Evaluation of Physicochemical and Biological Stability of 36-Months-Aged SB5 (Adalimumab Biosimilar) for 4 Weeks at Room Temperature

Introduction Tumor necrosis factor (TNF-alpha) inhibitors, such as adalimumab, have shown success in treating autoimmune inflammatory diseases but are associated with substantial financial burdens to the healthcare system. Biosimilars, which are highly similar to biologic agents, offer the potential...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Advances in therapy 2019-02, Vol.36 (2), p.442-450
Hauptverfasser:	Park, Dongkuk, Yun, Jihoon, Hwang, Su-Jeong, Park, Su Jin
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab - metabolism Adalimumab - therapeutic use Arthritis, Rheumatoid - drug therapy Autoimmune Diseases - drug therapy Biosimilar Pharmaceuticals - metabolism Biosimilar Pharmaceuticals - therapeutic use Cardiology Drug Stability Endocrinology Health technology assessment Humans Internal Medicine Medicine Medicine & Public Health Oncology Original Research Pharmacology/Toxicology Rheumatology Temperature Therapeutic Equivalency Tumor Necrosis Factor-alpha - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!